{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:50:12Z","timestamp":1790315412813,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.gastrohep.2022.12.002","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T15:23:51Z","timestamp":1672154631000},"page":"815-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["NAFLD and type 2 diabetes: A practical guide for the joint management"],"prefix":"10.1016","volume":"46","author":[{"given":"Idoia","family":"Genua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Iruzubieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Rodr\u00edguez-Duque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2022.12.002_bib0330","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu, European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388\u2013402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0335","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0340","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0345","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/liv.15323","article-title":"Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology","volume":"42","author":"Calleja","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0350","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0355","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/gut.2004.052167","article-title":"Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study","volume":"54","author":"Davila","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0360","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0365","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.13264","article-title":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis","volume":"31","author":"Ballestri","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0370","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2020.02.028","article-title":"Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH","volume":"73","author":"Ampuero","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0375","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2337\/dc16-1787","article-title":"Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action","volume":"40","author":"Bril","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0380","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/dme.13540","article-title":"Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital","volume":"35","author":"Marjot","year":"2018","journal-title":"Diabet Med"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-015-0607-4","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms","volume":"15","author":"Saponaro","year":"2015","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0390","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0395","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/apt.15660","article-title":"Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease","volume":"51","author":"Henson","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0400","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0405","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0410","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/hep.28253","article-title":"Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study","volume":"63","author":"Wong","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0415","doi-asserted-by":"crossref","first-page":"e0142937","DOI":"10.1371\/journal.pone.0142937","article-title":"Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA study)","volume":"10","author":"K\u00e4r\u00e4j\u00e4m\u00e4ki","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0420","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0425","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.gastrohep.2017.12.003","article-title":"Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline","volume":"41","author":"Aller","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0430","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/liv.14807","article-title":"National digestive disease specialists survey on cardiovascular risk management in non-alcoholic fatty liver disease in Spanish hospitals","volume":"41","author":"Iruzubieta","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0435","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0440","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0445","first-page":"251","article-title":"Cardiorenal syndrome: pathophysiology","volume":"37","author":"Kumar","year":"2019","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0450","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0455","doi-asserted-by":"crossref","first-page":"109067","DOI":"10.1016\/j.diabres.2021.109067","article-title":"Novel strategies for glycaemic control and preventing diabetic complications applying the clustering-based classification of adult-onset diabetes mellitus: a perspective","volume":"180","author":"Tanabe","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0460","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/liv.15404","article-title":"Management of NAFLD in primary care settings","volume":"42","author":"Wong","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0465","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cgh.2019.05.051","article-title":"Development and validation of hepamet fibrosis scoring system \u2013 a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis","volume":"18","author":"Ampuero","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0470","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.cgh.2018.12.031","article-title":"Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0475","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH \u2013 current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0480","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/jim-2018-000864","article-title":"Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus","volume":"67","author":"Bril","year":"2019","journal-title":"J Investig Med"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0485","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12876-019-1039-4","article-title":"Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease","volume":"19","author":"Srivastava","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0490","first-page":"S136","article-title":"Serum-based Metabolomics-Advanced StEatohepatitis Fibrosis Score (MASEF) fot the non-invasive identification of patients with non-alcoholic steatohepatitis with significant fibrosis","volume":"73","author":"Noureddin","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0495","first-page":"949A","article-title":"Diagnostic performance of metabolomic test to detect nonalcoholic esteatohepatitis and significant fibrosis in patients at high risk of progressive fatty liver disease","volume":"74","author":"Mayo","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0500","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0505","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","article-title":"Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial","volume":"7","author":"Lean","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0510","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.3390\/ijerph16173011","article-title":"Diet and non-alcoholic fatty liver disease: the mediterranean way","volume":"16","author":"Abenavoli","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0515","doi-asserted-by":"crossref","first-page":"104192","DOI":"10.1016\/j.ebiom.2022.104192","article-title":"Exercise training enhances muscle mitochondrial metabolism in diet-resistant obesity","volume":"83","author":"Pileggi","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0520","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review","volume":"66","author":"Hashida","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0525","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed Rep"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0530","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0535","doi-asserted-by":"crossref","first-page":"e013927","DOI":"10.1136\/bmjopen-2016-013927","article-title":"Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Liao","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0540","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0545","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0550","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0555","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0560","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0565","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0570","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14740\/gr1498","article-title":"Statin use in patients with chronic liver disease and cirrhosis: current evidence and future directions","volume":"15","author":"Kreidieh","year":"2022","journal-title":"Gastroenterol Res"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0580","doi-asserted-by":"crossref","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","article-title":"Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case\u2013control study","volume":"116","author":"Lee","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0585","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0590","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/MCG.0000000000001260","article-title":"Statin use is protective against hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a case\u2013control study","volume":"54","author":"German","year":"2020","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0595","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.14309\/ajg.0000000000001347","article-title":"Chemopreventive effect of statin on hepatocellular carcinoma in patients with nonalcoholic steatohepatitis cirrhosis","volume":"116","author":"Pinyopornpanish","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0600","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0605","doi-asserted-by":"crossref","unstructured":"Committee ADAPP. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of medical care in diabetes\u20142022. Diabetes Care. 2022;45:S113\u201324.","DOI":"10.2337\/dc22-S008"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0610","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa1401329","article-title":"Bariatric surgery versus intensive medical therapy for diabetes \u2013 3-year outcomes","volume":"370","author":"Schauer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0615","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0620","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1053\/j.gastro.2009.04.052","article-title":"Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease","volume":"137","author":"Mathurin","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0625","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0630","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cgh.2020.04.068","article-title":"Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis","volume":"19","author":"Bazerbachi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0635","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0140-6736(22)01280-6","article-title":"Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial","volume":"400","author":"Abu Dayyeh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0640","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.soard.2019.11.012","article-title":"Safety and efficacy of endoscopic sleeve gastroplasty worldwide for treatment of obesity: a systematic review and meta-analysis","volume":"16","author":"Singh","year":"2020","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0645","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1186\/s13063-021-05695-7","article-title":"Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): study protocol for a randomized controlled trial (TESLA-NASH study)","volume":"22","author":"Lav\u00edn-Alconero","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.gastrohep.2022.12.002_bib0650","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.12652","article-title":"Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor","volume":"18","author":"Defronzo","year":"2016","journal-title":"Diabetes Obes Metab"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570522003119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570522003119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:46:48Z","timestamp":1759322808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570522003119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0210570522003119"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2022.12.002","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NAFLD and type 2 diabetes: A practical guide for the joint management","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2022.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}